Australia markets close in 51 minutes

Evoke Pharma, Inc. (EVOK)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.2300-0.0300 (-2.38%)
At close: 03:51PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.2600
Open1.2300
Bid1.1100 x 900
Ask1.5200 x 1000
Day's range1.2000 - 1.2350
52-week range0.9190 - 5.9600
Volume10,062
Avg. volume14,277
Market cap4.112M
Beta (5Y monthly)0.32
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent

    GIMOTI now holds four listed patents with coverage through 2029SOLANA BEACH, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that its recently issued U.S. patent related to GIMOTI, No. 11,813,231 is now listed in the U.S. Food and Drug Administration (FDA) publication, “Approved Drug Products with Th

  • GlobeNewswire

    United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI

    The Company Will Submit for FDA Orange-Book Listing in the Near TermSOLANA BEACH, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,813,231 titled “Nasal Formulations of Metoclopramide”, pertaining to the Company’s com

  • GlobeNewswire

    Evoke Pharma Reports Third Quarter 2023 Financial Results

    38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase Compared to Q2 2023; 95% Increase Year-Over-Year “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” Presented at The American College of Gastroenterology (ACG) 2023 Annual Meeting SOLANA BEACH, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDA